After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Sciences presented the first data from its ongoing Phase 1 study investigating two novel, once-yearly formulations of ...
Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...
The Trump administration has cut around 100 employees, or roughly 10%, of the federal agency that oversees mental and ...
News-Medical.Net on MSN2h
Gilead’s capsid revolution meets our capsid solutions: Sino Biological – Engineering the tools to outsmart HIVGilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
A clinical trial published in The Lancet suggests that a yearly injection of lenacapavir, developed by Gilead Sciences, is ...
A yearly injection to protect against HIV is safe and shows promise as a prevention method with long-lasting effects, according to the results of a c ...
The new study, published in The Lancet, is the first to evaluate a once-yearly injection of an HIV pre-exposure prophylaxis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback